Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease

被引:198
|
作者
Torres, Vicente E. [1 ]
Harris, Peter C. [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA
来源
关键词
PROTEIN-KINASE-A; LAMININ-BINDING INTEGRINS; LONG-ACTING SOMATOSTATIN; CYST EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; CYCLIC-AMP; RECEPTOR SUBTYPES; LIVER-DISEASE; IN-VITRO; PKD1; HAPLOINSUFFICIENCY;
D O I
10.1681/ASN.2013040398
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Polycystic kidney disease (PKD) is a leading cause of ESRD worldwide. In PKD, excessive cell proliferation and fluid secretion, pathogenic interactions of mutated epithelial cells with an abnormal extracellular matrix and alternatively activated interstitial macrophages, and the disruption of mechanisms controlling tubular diameter contribute to cyst formation. Studies with animal models suggest that several diverse pathophysiologic mechanisms, including dysregulation of intracellular calcium levels and cAMP signaling, mediate these cystogenic mechanisms. This article reviews the evidence implicating calcium and cAMP as central players in a network of signaling pathways underlying the pathogenesis of PKD and considers the therapeutic relevance of treatment strategies targeting cAMP signaling.
引用
收藏
页码:18 / 32
页数:15
相关论文
共 50 条
  • [21] Cytosolic Calcium-Dependence of Elevated cAMP in Polycystic Kidney Disease
    Chu, Wen-Feng
    Komlosi, Peter
    Haycraft, Courtney J.
    Zhang, Zhi-Ren
    Bell, Phillip Darwin
    FASEB JOURNAL, 2008, 22
  • [22] Targeting chloride transport in autosomal dominant polycystic kidney disease
    Jouret, Francois
    Devuyst, Olivier
    CELLULAR SIGNALLING, 2020, 73
  • [23] Advances in the pathogenesis and treatment of polycystic kidney disease
    Patel, Vishal
    Chowdhury, Renuka
    Igarashi, Peter
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (02): : 99 - 106
  • [24] The Treatment of Autosomal Dominant Polycystic Kidney Disease
    Kuehn, E. Wolfgang
    Walz, Gerd
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2015, 112 (51-52): : 884 - 890
  • [25] A Case for Water in the Treatment of Polycystic Kidney Disease
    Torres, Vicente E.
    Bankir, Lise
    Grantham, Jared J.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (06): : 1140 - 1150
  • [26] Rationale for early treatment of polycystic kidney disease
    Grantham, Jared J.
    PEDIATRIC NEPHROLOGY, 2015, 30 (07) : 1053 - 1062
  • [27] Pathogenesis and treatment of hypertension in polycystic kidney disease
    Neumann, J
    Ligtenberg, G
    Klein, IHHT
    Blankestijn, PJ
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (05): : 517 - 521
  • [28] Rationale for early treatment of polycystic kidney disease
    Jared J. Grantham
    Pediatric Nephrology, 2015, 30 : 1053 - 1062
  • [29] Treatment of autosomal dominant polycystic kidney disease
    Torra, Roser
    MEDICINA CLINICA, 2014, 142 (02): : 73 - 79
  • [30] Therapeutic Advances in the Treatment of Polycystic Kidney Disease
    Riella, Cristian
    Czarnecki, Peter G.
    Steinman, Theodore I.
    NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 297 - 302